reboxetine

Phase 2Small molecule

UUniversity of Zurich

reboxetine is one of 142 small molecule programs targeting Post-Traumatic Stress Disorder. It is currently in Phase 2.

Indications

Total Trials

Active Trials

141

Competitors

Pipeline

Status by Indication[3][1]

Indication

Post-Traumatic Stress DisorderRecruiting

Adverse EffectActive, not recruiting

PTSDRecruiting

SurgeryRecruiting

AINCompleted

ISSCompleted

HumansCompleted

Post-Traumatic Stress DisorderPhase 2

Recruiting

Adverse EffectPreclinical

Active, not recruiting

PTSDPhase 2

Recruiting

SurgeryPhase 2

Recruiting

AINPreclinical

Completed

ISSPreclinical

Completed

HumansPreclinical

Completed

Competition

Competitive Landscape

63 competitors in Post-Traumatic Stress Disorder

#DrugCompanyPhaseTrials

Minipress

Pfizer

Approved

5 2

Lexapro

AbbVie

Approved

5 3

Epidiolex

Jazz Pharmaceuticals

Approved

2 4

Namenda

AbbVie

Approved

1 5

Marinol

Jazz Pharmaceuticals

Approved

1 6

Revia

Teva

Approved

1 7

Zoloft

VViatris Specialty LLC

Approved

7 8

Inderal

WWyeth-Lederle Vaccines

Approved

6 9

Paxil

SSebela Pharmaceuticals Development LLC

Approved

4 10

Cymbalta

Jazz Pharmaceuticals

Approved

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Recruiting

Post-Traumatic Stress Disorder

NCT05133804

Q3 2028

Phase 2Recruiting

PTSD

NCT07771530

Clinical

Trials by Indication[1]

Major Depressive Disorder1 trial

Effect of Escitalopram vs. Reboxetine on Gastro-intestinal Sensitivity of Patients With Major Depressive Disorder

Unknown status·HHospital Universitari Vall d'Hebron Research Institute·Phase 4·NCT00209807·42 enrolled

Adolescent1 trial

Reboxetine Treatment in Depressed Children and Adolescents an 8-Week, Open Study

Unknown status·GGeha Mental Health Center·Phase 4·NCT00426946·60 enrolled

Adverse Effect1 trial

Augmentation of the Antidepressant Action of Sertraline With Triiodothyronine (T3)and Reboxetine: Clinical Efficacy, Adverse Effects and Predictors of Response.

Completed·HHadassah Medical Organization·N/A·NCT00421369·35 enrolled

AIN1 trial

Studying the Role of Brain Molecules for Decision Making

Completed·UUniversity of Zurich·N/A·NCT04384562·160 enrolled

Antidepressants1 trial

Antidepressants and Bone Mineral Density

Completed·GGuiyang Medical University·Phase 3·NCT02179268·203 enrolled

11 more indications

Schizophrenia1 trial

Reboxetine and Citalopram as an Adjunct Treatment to Second Generation Antipsychotics in the Treatment of Negative Symptoms of Schizophrenia

Unknown status·FFundació Sant Joan de Déu·Phase 4·NCT01300364·249 enrolled

ISS1 trial

The Role of Dopaminergic and Noradrenergic Neurotransmission in Value- and Salience-based Decision-Making

Completed·UUniversity of Zurich·N/A·NCT04371146·120 enrolled

Surgery1 trial

Reboxetine for Sleep Apnoea After ENT Surgery

Recruiting·FFlinders University·Phase 2·NCT05978505·20 enrolled

Single Dose1 trial

Effects of Single Dose Citalopram and Reboxetine on Urethral and Anal Closure Function on Healthy Female Subjects

Completed·UUniversity Hospital Bispebjerg and Frederiksberg·Phase 1·NCT04097288·24 enrolled

Methamphetamine1 trial

Interaction Between Reboxetine and 3,4-Methylenedioxymethamphetamine: Pharmacodynamics (PD) and Pharmacokinetics (PK)

Completed·UUniversity Hospital, Basel, Switzerland·Phase 1·NCT00886886·16 enrolled

Transcranial Direct Current Stimulation1 trial

Enhancement of Motor Function with Reboxetine and Transcranial Direct Current Stimulation

Completed·UUniversitätsklinikum Hamburg-Eppendorf·Phase 4·NCT00853866·12 enrolled

Major Depression1 trial

Cognitive Flexibility in Major Depression in the Course of Pharmacological and Psychotherapeutic Treatment

Completed·ZZentrum für Integrative Psychiatrie·N/A·NCT00993876·45 enrolled

Humans1 trial

Noradrenaline, Acetylcholine and Dynamic Learning in Healthy Humans

Completed·UUniversity of Oxford·N/A·NCT03957174·107 enrolled

PTSD1 trial

Evaluating the Efficacies of an Innovative Pharmacological Treatment (Reboxetine Plus Ritalin) Versus Dog-Assisted Therapy in PTSD: A Randomized Controlled Trial

Recruiting·UUniversity of Haifa·Phase 2·NCT07771530·160 enrolled

Post-Traumatic Stress Disorder1 trial

The Relation Between Attentional, Sensory and Emotional Dysregulation in Adults With Posttraumatic Stress Disorder: a Double-blind, Placebo-controlled Randomized Controlled Trial of the Combined Treatment With Reboxetine and Methylphenidate

Recruiting·UUniversity of Haifa·Phase 2·NCT05133804·53 enrolled

Unspecified1 trial

Pharmacovigilance in Gerontopsychiatric Patients

Terminated·HHannover Medical School·Phase 3·NCT02374567·407 enrolled

Sources

References

[1]
ClinicalTrials.gov — 16 trial records for reboxetine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — reboxetine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for reboxetine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Zurich company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: UUniversity of Zurich

reboxetine

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q3 2028

Trials by Indication[1]

Major Depressive Disorder1 trial

Adolescent1 trial

Adverse Effect1 trial

AIN1 trial

Antidepressants1 trial

Schizophrenia1 trial

ISS1 trial

Surgery1 trial

Single Dose1 trial

Methamphetamine1 trial

Transcranial Direct Current Stimulation1 trial

Major Depression1 trial

Humans1 trial

PTSD1 trial

Post-Traumatic Stress Disorder1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News